Results for: Aurora Cannabis

Canadian medical marijuana giant Aurora Cannabis Inc. reported strong second-quarter financial results, with revenue reaching CA$81.1 million, driven by robust growth in its global medical cannabis business. The company’s international revenue surged 93%, exceeding Canadian medical revenue for the first time, highlighting its strategic focus on expanding into lucrative international markets. Aurora’s Q2 2025 performance also saw a significant increase in adjusted EBITDA and a positive outlook for the coming quarters.

Cannabis stocks are experiencing a resurgence, with major players like Canopy Growth, Aurora Cannabis, SNDL, and OrganiGram demonstrating upward momentum. While each stock shows promise, their future prospects are influenced by key technical indicators. This article provides a comprehensive analysis of these stocks, outlining their current positions and potential future trajectories.

Canadian cannabis company Aurora Cannabis has secured a US patent for its groundbreaking research on auto-flowering technology in cannabis. This innovation could revolutionize cannabis cultivation, particularly in high-latitude regions, by allowing plants to automatically transition to the flowering stage, independent of light cycles. Aurora’s research also focuses on improving potency, yield, and overall efficiency in cannabis production.

Aurora Cannabis and Vectura Fertin Pharma have partnered to launch a new CBD lozenge in Canada. This marks Vectura Fertin Pharma’s first medical cannabis CBD lozenge in the Canadian market and represents a significant step forward in their collaboration with Aurora. The lozenge, manufactured by Cogent International, a subsidiary of Vectura Fertin Pharma, offers a novel dissolvable format for easy dosing.

Aurora Cannabis has partnered with Vectura to launch a CBD lozenge, providing an alternative consumption method for medical cannabis patients. The company also reports strong international sales growth and improved financial performance, showcasing its commitment to innovative products and expansion.

Germany’s cannabis market is rapidly expanding, with Tilray, Aurora, and Demecan emerging as key players in domestic cultivation. These companies are strategically positioned to capitalize on the growing medical cannabis market, projected to reach €1.7 billion by 2025. This article delves into the operations and contributions of each company, highlighting their role in shaping Germany’s cannabis landscape.

Cannabis stocks have emerged as a contentious but lucrative investment option. Buoyed by growing public support for legalization, favorable regulatory developments, and speculation surrounding upcoming presidential elections, these stocks are poised for further gains. Investors seeking exposure to this industry can consider companies like Innovative Industrial Properties (IIPR), Trulieve Cannabis (TCNNF), and Aurora Cannabis (ACB).